Bucillamine is a new disease modifying antirheumatic drug developed in Japan with a chemical structure similar to that of d-penicillamine. The side effects of bucillamine include nausea, rashes, leukopenia and nephropathies in patients with RA, which ...
Bucillamine is a new disease modifying antirheumatic drug developed in Japan with a chemical structure similar to that of d-penicillamine. The side effects of bucillamine include nausea, rashes, leukopenia and nephropathies in patients with RA, which are similar to those of d-penicillamine. Membranous glomerulonephritis occurs rarely as a complication of bucillamine treatment. If a patient with rheumatoid arthritis has proteinuria or edema during treatment, bucillamine-induced membranous glomeru lonephritis should be suspected as the cause of proteinuria. In those cases, renal biopsy should be taken for diagnosis and proper treatment. We report a case of bucillamine-induced membranous glomeruronephritis in rheumatoid arthritis confirmed by renal biopsy, which improved by conservative treatment.